https://www.selleckchem.com/products/ABT-263.html
3%) at an average of 23.6 months. The NTR cohort ( n = 27) did not experience tumor recurrence. Risk of tumor recurrence was positively correlated with preoperative tumor size ( p = 0.002), size of residual tumor ( p less then 0.001), and STR ( p less then 0.001). Facial nerve outcomes of HB1-2 were observed in the majority of patients in both cohorts (74.1% NTR, 56% STR), though NTR was associated with a higher likelihood of facial nerve recovery ( p = 0.003). Conclusion GTR remains the gold standard as long as facial nerve o
Curtir
Comentario
Compartilhar
